A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
Plasma levels of a2-plasmin inhibitor (a2PI), plasmin-a2PI complex and cross-linked fibrin derivatives (XDP) were measured in 8 patients (12 episodes) with thromboembolic disorders on the initial administration of urokinase. In conjunction with a decrease in plasma a2PI activity and antigen, plasmin-a2PI complex increased following urokinase infusion in all cases except one who received a low dose (60,000 units) of urokinase. However, changes in XDP were variable among the patients. Plasma XDPdoi:10.1620/tjem.153.295 pmid:2964745 fatcat:wmsxbnbqknfetjdbp73dkndcym